NCT05513742View on ClinicalTrials.gov

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

April 28, 2025

Study Completion Date

May 15, 2025

Conditions
Metastatic Colorectal CancerColon CancerRectal Cancer
Interventions
DRUG

CTX-009

IV infusion administered on day 1 and 15 of every 28-day cycle

Trial Locations (7)

33705

Florida Cancer Specialists & Research Institute - North, St. Petersburg

33916

Florida Cancer Specialists & Research Institute - South, Fort Myers

37203

SCRI Oncology Partners, Nashville

43219

Zangmeister Cancer Center, Columbus

71913

Genesis Cancer and Blood Institute, Hot Springs

75230

Mary Crowley Cancer Research, Dallas

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Compass Therapeutics

INDUSTRY

NCT05513742 - A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter